ADARx Pharmaceuticals Announces Dosing of First Cohort in Phase 1 Clinical Study of ADX-324

SAN DIEGO–(BUSINESS WIRE)–ADARx Pharmaceuticals, Inc., a clinical stage biotechnology company developing RNA-targeting therapeutics, today announced the dosing of the first cohort in a Phase 1 clinical study of ADX-324 for the treatment of hereditary angioedema (HAE). HAE is a rare genetic disease that causes painful, rapid, and potentially life-threatening swelling attacks. “We are very excited to be advancing our first candidate that utilizes our proprietary PLR™ delivery platform and SPE™
Click here to view original post